// App-Quantinova.ai

OP173 : Consistent reduction in stent thrombosis risk at 5 years with a zotarolimus-eluting stent versus a sirolimus-eluting stent in men and women

Researchers

Presenter

  • Ten Haaf M

Principal Investigators

  • Boersma E

  • Wijns W

  • Steg G

  • Mauri L

  • Rademaker-Havinga T

  • Bousquette L

  • Appelman Y

  • Camenzind E

Medical Centers

  • Cardiovascular Center, OLV Hospital, Aalst, Belgium

  • Universite de Geneve, Geneva, Switzerland

  • Departement Hospitalo-Universitaire FIRE, Paris, France

Locations

  • France

  • Switzerland

  • Belgium

Companies

  • Medtronic Plc

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Myocardial infarction

  • Diabetes

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • sirolimus

  • ZoMaxx

  • Clopidogrel bisulfate

  • Ticlopidine Hydrochloride

  • Rapacan

  • Aspirin

  • Albyl-E

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved